Ipsen Pharma GmbH
Pharmaceutical Companies · München
Ipsen Pharma GmbH is the German subsidiary of französischen Pharmaunternehmens Ipsen S, based in München. Key areas: Onkologie (Cabometyx®, Somatuline®), Neurologie (Dysport®) und seltene Erkrankungen.
Content in German
The detailed company information on this page is provided in the original German language. You can use your browser's built-in translation feature to view it in English.
Right-click on the page and select "Translate to English" or use the translation icon in your browser's address bar.
Ipsen Pharma GmbH Address & Contact
Company profile
1929
Founded
5.000+ (global)
Employees
Overview of Ipsen Pharma GmbH
Ipsen Pharma GmbH, the German subsidiary of the renowned French specialty pharmaceutical company Ipsen S.A., operates in the fields of oncology, neurology, and rare diseases. The company is headquartered in Munich, where it strategically and operationally organizes the care of the German specialist medical market. Ipsen focuses on innovative therapeutic solutions tailored to the specific needs of patients in these areas. With a clear commitment to research and development, Ipsen strives to improve patients' quality of life through high-quality products.
Oncology and Neurology
In the field of oncology, Ipsen has made a name for itself with Cabometyx (Cabozantinib), which is used to treat renal cell carcinomas, hepatocellular carcinoma, and thyroid carcinoma. This product belongs to the selective tyrosine kinase inhibitors and has proven its efficacy in clinical studies. Additionally, Decapeptyl (Triptorelin) plays a central role in hormonal therapy for cancers in the fields of gynecology and oncology by inhibiting the growth of hormone-dependent tumors.
In the field of neurology, Ipsen distributes Dysport, a botulinum toxin preparation, which finds application particularly in the treatment of spasticity, cervical dystonia, and also in aesthetics. This versatility makes Dysport an important product in the portfolio. Moreover, the somatostatin analogue Somatuline (Lanreotide) is used for the treatment of neuroendocrine tumors, securing Ipsen a leading role in this specialized segment of oncology.
Regulatory Classification
Ipsen Pharma GmbH is subject to strict regulatory requirements in Germany, as established by the Medicinal Products Act (AMG) and the regulations for its implementation. Each product must undergo comprehensive approval by the competent authorities, such as the Federal Institute for Drugs and Medical Devices (BfArM). Ipsen is actively committed to compliance with these regulations and ensuring drug safety, which is essential to maintain the trust of doctors and patients.
Regional Significance and Location Munich
Munich is not only the headquarters of Ipsen Germany, but also a significant location in the pharmaceutical industry. The city offers access to a variety of specialists and clinics, including leading institutions like the LMU Hospital, enabling Ipsen to conduct close collaborations and clinical studies. These regional partnerships are crucial to fostering the exchange between research and application and bringing innovative therapies quickly into clinical practice.
The Bavarian capital has also positioned itself as a center for biomedical research, increasing the location's attractiveness for Ipsen. The close cooperation with scientific institutions and other pharmaceutical companies promotes knowledge exchange and the development of new approaches in the treatment of complex medical conditions.
Particularities of Ipsen Pharma GmbH
One noteworthy aspect is Ipsen's commitment to research and development of new therapeutic approaches. The company continuously invests in clinical studies to further validate the efficacy and safety of its products. Furthermore, Ipsen adopts a patient-centered approach to ensure that the needs of patients are always at the forefront of all activities.
Another feature of Ipsen is its orientation towards the latest scientific knowledge and technological developments. The company is purposefully working on the development of new formulations and combination therapies to offer even greater therapeutic benefits. This innovative strength, combined with a solid regulatory foundation, is the basis on which Ipsen builds its future.
More pharmaceutical companies in Germany | pharmaceutical companies in Munich | pharmaceutical companies in Bavaria
Frequently asked questions about Ipsen Pharma GmbH
What does Ipsen Pharma GmbH do?
Die Ipsen Pharma GmbH develops Medikamente and therapeutische Lösungen for the Bereiche Onkologie, Neurowissenschaften and seltene Krankheiten. Krebserkrankungen, Störungen im Hormonhaushalt and Störungen im Bewegungsapparat gehören zu ihrem Tätigkeitsfeld. Einer ihrer Schwerpunkte liegt on the development of therapeutischen Lösungen for Krankheiten, the eine schwere Beeinträchtigung for the Betroffenen darstellen.
More Pharmaceutical Companies in München
Pharmaceutical Companies in Germany
Related areas in healthcare
Pharmaceutical Companies by location
About Pharmaceutical Companies
Germany is one of the world's leading pharmaceutical nations, home to more than 1,000 pharmaceutical businesses employing approximately 130,000 people (vfa 2023). Companies operating in this sector develop, manufacture and distribute medicines across the entire value chain, from early-stage research and clinical trials through to market authorisation and commercial distribution. In Germany, every manufacturer of medicinal products must hold a manufacturing authorisation (Herstellungserlaubnis) issued under Section 13 of the AMG (Arzneimittelgesetz, Germany's Medicinal Products Act). Medicines may only be placed on the market after receiving approval from either BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte, Germany's Federal Institute for Drugs and Medical Devices, broadly comparable to the FDA in the United States or the MHRA in the United Kingdom) or the European Medicines Agency (EMA) via the centralised procedure. All manufacturing sites are subject to regular GMP (Good Manufacturing Practice) inspections carried out by the competent pharmaceutical supervisory authority of the relevant German federal state. The sector covers prescription-only medicines (Rx), non-prescription OTC products, generics, biosimilars and active pharmaceutical ingredients (APIs). This directory lists pharmaceutical manufacturers, marketers and licence holders across all German federal states with full contact details, addresses and phone numbers.
Germany's Pharmaceutical Industry
Germany is consistently ranked among the top five pharmaceutical markets worldwide, generating annual revenues exceeding EUR 50 billion and accounting for the largest share of pharmaceutical production in continental Europe. The industry is represented by two major associations: vfa (Verband Forschender Arzneimittelhersteller), which represents research-based companies, and BAH (Bundesverband der Arzneimittel-Hersteller), which represents the broader manufacturer base including OTC and self-medication products. German pharmaceutical companies cover the full spectrum from global innovator corporations and mid-sized specialty manufacturers to generic producers and biotech firms. The country is a world leader in active pharmaceutical ingredient (API) production, biologics manufacturing and pharmaceutical chemistry. Key therapeutic areas of strength include oncology, cardiovascular medicine, immunology, neuroscience and rare diseases. Germany also serves as a significant export hub, with pharmaceutical products among the country's leading export categories. The sector benefits from a highly skilled workforce, world-class university research institutions and a dense network of research hospitals (Universitätsklinika) that facilitate clinical trial activity.
Regulatory Framework: BfArM, EMA and the AMG
The legal foundation for pharmaceutical activity in Germany is the Arzneimittelgesetz (AMG, German Medicinal Products Act), which regulates the authorisation, manufacture, import, distribution, labelling and pharmacovigilance of medicinal products. For English-speaking readers unfamiliar with the German regulatory landscape: BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is the national competent authority responsible for approving medicines marketed only in Germany, supervising narcotics, and maintaining the pharmacovigilance database. BfArM is a higher federal authority (Bundesoberbehörde) subordinate to the Federal Ministry of Health (Bundesministerium für Gesundheit). For medicines approved via the centralised EU procedure, the European Medicines Agency (EMA) grants a single marketing authorisation valid in all 27 EU member states. Germany is also home to the Paul-Ehrlich-Institut (PEI), a second federal authority that specifically handles biological medicines including vaccines, blood products and gene therapy products. Manufacturing sites are inspected by state-level pharmaceutical supervisory authorities (Landesbehörden) to verify GMP compliance, with findings entered into the EudraGMDP database operated by the EMA.
Regional Pharmaceutical Clusters in Germany
Germany's pharmaceutical industry is geographically distributed across several major regional clusters. The Rhine-Main area around Frankfurt and Leverkusen in North Rhine-Westphalia is home to some of Germany's largest pharmaceutical sites, including facilities belonging to global corporations with long histories in German chemistry and pharmaceuticals. Bavaria (particularly Munich, Penzberg and Marburg) is a second major hub, especially strong in biotechnology and biologics production. Baden-Württemberg, including cities such as Mannheim, Heidelberg and Biberach an der Riss, is home to several significant research-based manufacturers. Hamburg and the northern German region have a cluster of specialty and generic manufacturers. Berlin has a growing biotech scene connected to its research universities and the Charité hospital. Hesse is notable for its proximity to Frankfurt's logistics infrastructure and several major API manufacturers. Smaller but significant clusters exist in Saxony (Leipzig, Dresden) and Lower Saxony, benefiting from proximity to university research centres and historically established chemical industry sites.
Drug Classes and Product Segments
German pharmaceutical companies cover all major drug classes. Prescription (Rx) products account for the largest share of revenue; generics manufacturers such as Stada, ratiopharm (Teva) and Hexal produce chemically equivalent alternatives after patent expiry, significantly reducing costs for the healthcare system. Biologics and biosimilars are gaining ground rapidly: monoclonal antibodies, insulin analogues and recombinant growth factors require specialised biotech manufacturing facilities. OTC products (over-the-counter), i.e. medicines available without a prescription, represent a multi-billion-euro market served by companies such as Bayer Consumer Health, Stada and Klosterfrau. Homeopathic preparations, herbal medicines and dietary supplements form further regulated segments. Digitalisation is increasingly shaping the sector: Digital Health Applications (DiGA) have been reimbursable since 2020, and AI-assisted drug development is significantly shortening time-to-market.
What does a pharmaceutical company do?
Pharmaceutical companies develop, produce and distribute medicines. They cover the entire value chain from research and clinical trials through to market launch and distribution. In Germany, they are supervised by BfArM (the Federal Institute for Drugs and Medical Devices, comparable to the FDA or MHRA).
How are pharmaceutical companies regulated in Germany?
Pharmaceutical companies in Germany must hold a manufacturing authorisation under Section 13 of the AMG (German Medicinal Products Act). All authorised medicines require approval from either BfArM or the European Medicines Agency (EMA). Regular GMP (Good Manufacturing Practice) inspections ensure quality standards are maintained.
Where can I find contact details for pharmaceutical companies in Germany?
Industry associations such as vfa (Association of Research-Based Pharmaceutical Companies) and BPI (Federal Association of the German Pharmaceutical Industry) maintain member directories. Many companies also list their key contacts directly on their websites. Sanoliste provides a searchable directory of pharmaceutical companies in Germany sorted by federal state and city.
How many pharmaceutical companies are there in Germany?
Germany is home to more than 1,000 pharmaceutical companies employing approximately 130,000 people, according to vfa (the Association of Research-Based Pharmaceutical Companies) 2023 data. The sector includes multinational corporations, mid-sized specialty firms, generic manufacturers and biotech startups.
What is BfArM and what does it regulate?
BfArM (Bundesinstitut für Arzneimittel und Medizinprodukte) is Germany's Federal Institute for Drugs and Medical Devices. It is a higher federal authority within the portfolio of the Federal Ministry of Health and is responsible for approving medicines for the German market, monitoring drug safety (pharmacovigilance), regulating narcotics and controlled substances, and overseeing medical devices in Germany. It is broadly comparable to the FDA in the United States or the MHRA in the United Kingdom.
What is the difference between BfArM approval and EMA approval?
Medicines in Germany can be approved through two main routes. BfArM grants national marketing authorisations valid in Germany, or decentralised and mutual recognition procedure approvals valid in multiple EU states. The EMA (European Medicines Agency) grants centralised marketing authorisations valid in all 27 EU member states simultaneously, typically used for innovative biologic medicines, oncology drugs and products for rare diseases.
What does GMP mean in the context of German pharmaceutical manufacturing?
GMP stands for Good Manufacturing Practice. In Germany and the EU, GMP compliance is a legal requirement for all pharmaceutical manufacturers under the AMG and the EU GMP Guidelines (EudraLex Volume 4). GMP covers all aspects of production including premises, equipment, personnel qualification, process validation, documentation and quality control. Compliance is verified by regular inspections from the competent state pharmaceutical supervisory authority.